Theravance Biopharma, Inc. (NASDAQ:TBPH) Short Interest Update

Key Points

• Theravance Biopharma experienced a 25.3% increase in short interest from August 15 to August 31, reaching 4,460,000 shares.
• The company's stock has been upgraded to a "strong-buy" rating by several analysts, with a consensus target price of $23.00.
• Hedge funds have significantly increased their positions in Theravance Biopharma, with institutional investors now owning 99.10% of the company’s stock.

Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) was the target of a significant increase in short interest during the month of August. As of August 31st, there was short interest totaling 4,460,000 shares, an increase of 25.3% from the August 15th total of 3,560,000 shares. Currently, 9.6% of the company's shares are sold short. Based on an average daily trading volume, of 333,700 shares, the short-interest ratio is presently 13.4 days. Based on an average daily trading volume, of 333,700 shares, the short-interest ratio is presently 13.4 days. Currently, 9.6% of the company's shares are sold short.

Theravance Biopharma Trading Down 4.1%

Shares of TBPH traded down $0.59 during mid-day trading on Friday, reaching $13.88. 465,356 shares of the stock traded hands, compared to its average volume of 489,611. Theravance Biopharma has a 1 year low of $7.88 and a 1 year high of $14.55. The company has a market cap of $699.00 million, a price-to-earnings ratio of 57.83 and a beta of 0.04. The firm has a fifty day moving average price of $12.67 and a 200 day moving average price of $10.78.

Insider Buying and Selling

In related news, SVP Rhonda Farnum sold 10,000 shares of the company's stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $11.39, for a total value of $113,900.00. Following the completion of the sale, the senior vice president owned 326,918 shares in the company, valued at approximately $3,723,596.02. This represents a 2.97% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 6.90% of the company's stock.

Hedge Funds Weigh In On Theravance Biopharma

Several large investors have recently made changes to their positions in TBPH. GAMMA Investing LLC grew its position in Theravance Biopharma by 1,201.8% during the first quarter. GAMMA Investing LLC now owns 3,554 shares of the biopharmaceutical company's stock valued at $32,000 after buying an additional 3,281 shares during the period. Tower Research Capital LLC TRC lifted its holdings in shares of Theravance Biopharma by 18.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company's stock worth $55,000 after acquiring an additional 781 shares during the last quarter. AQR Capital Management LLC bought a new stake in shares of Theravance Biopharma during the 1st quarter worth approximately $101,000. R Squared Ltd lifted its holdings in Theravance Biopharma by 636.6% during the 1st quarter. R Squared Ltd now owns 12,522 shares of the biopharmaceutical company's stock valued at $112,000 after buying an additional 10,822 shares in the last quarter. Finally, ProShare Advisors LLC bought a new stake in Theravance Biopharma during the 4th quarter valued at $119,000. 99.10% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Wall Street Zen raised shares of Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a research note on Saturday, August 16th. BTIG Research lifted their target price on shares of Theravance Biopharma from $24.00 to $25.00 and gave the stock a "buy" rating in a research note on Friday, June 27th. Jones Trading raised Theravance Biopharma to a "strong-buy" rating and set a $24.00 target price for the company in a research report on Tuesday, June 17th. B. Riley began coverage on shares of Theravance Biopharma in a report on Friday, September 12th. They issued a "buy" rating and a $28.00 target price on the stock. Finally, Zacks Research lowered Theravance Biopharma from a "strong-buy" rating to a "hold" rating in a report on Monday, September 15th. Two equities research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat, Theravance Biopharma presently has a consensus rating of "Buy" and an average target price of $23.00.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.